DOXAZOSIN/FINASTERIDA MIP 4mg / 5mg tablets medication leaflet

G04CA55 doxazosin + finasteride • Genito urinary system and sex hormones | Drugs used in benign prostatic hypertrophy | Alpha-adrenoreceptor antagonists

The combination of doxazosin and finasteride is used for the treatment of moderate to severe symptoms of benign prostatic hyperplasia. Doxazosin relaxes the smooth muscles in the prostate and bladder, while finasteride reduces prostate size by inhibiting the conversion of testosterone to dihydrotestosterone.

The medication is taken orally, as directed by a doctor, usually once daily. It is important to follow the treatment duration to achieve maximum benefits.

Side effects may include dizziness, decreased libido, erectile dysfunction, or orthostatic hypotension. In rare cases, severe allergic reactions or gynecomastia may occur.

This combination is not recommended for patients with hypersensitivity to any of the components or severe hepatic impairment.

General data about DOXAZOSIN/FINASTERIDA MIP 4mg / 5mg

Substance: doxazosin + finasteride

Date of last drug list: 01-06-2025

Commercial code: W71100003

Concentration: 4mg / 5mg

Pharmaceutical form: tablets

Quantity: 90

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: MIP PHARMA GMBH - GERMANIA

Holder: MIP PHARMA GMBH - GERMANIA

Number: 16003/2025/03

Shelf life: 3 years

Other substances similar to doxazosin + finasteride